Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

REUMATOLOGISK SPECIALLÆGEKLINIK ApS LONE SVENDSEN Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 0.4% 0.4%   Bankruptcy risk   1.9% 1.3% 1.5% 1.8% 7.6% 9.5% 9.4% 9.4%   Credit score (0-100)   71 81 77 70 31 25 26 26   Credit rating   A A A A BB BB BB BB   Credit limit (kDKK)   0.4 28.9 10.0 2.1 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   2,016 2,125 2,158 2,500 3,789 -74.6 0.0 0.0   EBITDA   1,087 785 1,082 1,216 2,670 -74.6 0.0 0.0   EBIT   858 620 976 1,176 2,653 -74.6 0.0 0.0   Pre-tax profit (PTP)   857.5 619.8 975.1 1,170.4 2,469.3 -16.7 0.0 0.0   Net earnings   668.8 483.4 760.4 945.8 1,882.6 -16.7 0.0 0.0   Pre-tax profit without non-rec. items   858 620 975 1,170 2,469 -16.7 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024e N/A 2025e N/A Tangible assets total   313 203 155 117 0.0 0.0 0.0 0.0   Shareholders equity total   799 1,282 934 1,880 3,650 3,519 3,276 3,276   Interest-bearing liabilities   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   1,247 1,639 1,494 2,364 4,201 3,551 3,276 3,276   Net Debt   -577 -1,072 -926 -1,836 -3,917 -3,529 -3,276 -3,276     See the entire balance sheet 1000.0 Volume  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   2,016 2,125 2,158 2,500 3,789 -74.6 0.0 0.0   Gross profit growth   -4.7% 5.4% 1.6% 15.8% 51.5% 0.0% 0.0% 0.0%   Employees   2 2 2 2 1 0 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% -50.0% -100.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   1,247 1,639 1,494 2,364 4,201 3,551 3,276 3,276   Balance sheet change%   -51.8% 31.4% -8.8% 58.2% 77.7% -15.5% -7.7% 0.0%   Added value   858.0 620.1 976.3 1,175.9 2,652.6 -74.6 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -448 -310 -154 -79 -134 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 5.0 -1.0 0.0 0.0   1000.0 Profitability  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   42.6% 29.2% 45.2% 47.0% 70.0% 100.0% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   44.7% 43.0% 62.3% 61.0% 83.0% -0.4% 0.0% 0.0%   ROI %   57.2% 58.6% 87.6% 83.6% 98.5% -0.4% 0.0% 0.0%   ROE %   45.8% 46.5% 68.6% 67.2% 68.1% -0.5% 0.0% 0.0%   1000.0 Solidity  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024e N/A 2025e N/A Equity ratio %   64.0% 78.2% 62.5% 79.5% 86.9% 99.1% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -53.1% -136.6% -85.6% -151.0% -146.7% 4,727.6% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Liquidity  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024e N/A 2025e N/A Quick Ratio   1.9 3.8 2.2 4.4 7.6 111.3 0.0 0.0   Current Ratio   1.9 3.8 2.2 4.4 7.6 111.3 0.0 0.0   Cash and cash equivalent   577.0 1,072.2 926.3 1,836.2 3,916.7 3,528.8 0.0 0.0   1000.0 Capital use efficiency  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   368.9 983.9 671.6 1,655.9 2,838.8 2,657.7 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   429 310 488 588 2,653 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   544 392 541 608 2,670 0 0 0   EBIT / employee   429 310 488 588 2,653 0 0 0   Net earnings / employee   334 242 380 473 1,883 0 0 0